Why the study?
Discourse continues regarding optimal dual antiplatelet therapy duration after percutaneous coronary intervention to balance major cardiovascular or cerebrovascular events and bleeding risk, especially as newer stent designs support shorter therapy.
Does short-term dual antiplatelet therapy reduce bleeding risk compared to long-term therapy in patients following percutaneous coronary intervention?
Does short-term dual antiplatelet therapy reduce bleeding risk compared to long-term therapy in patients following percutaneous coronary intervention?
This review highlights the paradigm shift towards shortened DAPT duration following PCI to minimize bleeding risk, supported by newer generation drug-eluting stents.
No takes yet. Share an insight, caveat, or question.
May support shorter DAPT post-PCI with modern stents; leaves open definitive guidance pending randomized confirmation.
Tang et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: